Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease pharmaceutical company's lead asset POLB 001.
English says that Poolbeg is "in a good position" for partnering in general, adding that the company is "really open" to different types of deals for lead asset POLB 001.